Tests ZGGS18 with ZG005 in adults with advanced solid tumors
Tests two drugs together in adults with advanced solid tumors, including cervical and lung cancer.
Plain-language title generated from the registry record
Registry title: Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumors, including cervical cancer, liver cancer, neuroendocrine tumors and lung cancer, whose standard treatment failed or was not tolerated.
- Age
- 18 to 75 years
- Sex
- Men and women can join
- Disease stage
- Advanced solid tumors, confirmed by tissue or cell examination (histopathology or cytology)
- Earlier treatment
- Standard treatment has failed or was not tolerated
Main reasons for not taking part
- Cancer has spread to the brain or spinal cord (CNS metastases)
- Another cancer within the last 5 years
- Any other reason the investigator judges the person unsuitable for the study
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06938880, who can take part
Where in China
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Trial code
- NCT06938880
- Record updated
- 5 January 2026
- Original description
This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.Read full original descriptionShow less
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors, Including Cervical Cancer, Hepatocellular Carcinoma, Neuroendocrine Tumors, and Lung Cancer
This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.
Inclusion: Fully understand this study and voluntarily sign the ICF; Age 18-75 years, no gender restriction; Patients with advanced solid tumors who have failed standard treatment or are intolerant to standard treatment, as confirmed by histopathology or cytology.
Exclusion: Other malignancies within 5 years; Medical history, CT scan, or MRI indicates the presence of CNS metastases; Any other reason deeming the participant unsuitable for the study, as judged by the investigator.